Literature DB >> 26730678

Diverse Nrf2 Activators Coordinated to Cobalt Carbonyls Induce Heme Oxygenase-1 and Release Carbon Monoxide in Vitro and in Vivo.

Aniket Nikam1,2, Anthony Ollivier3, Michael Rivard3, Jayne Louise Wilson1,2, Kevin Mebarki3, Thierry Martens3, Jean-Luc Dubois-Randé4, Roberto Motterlini1,2, Roberta Foresti1,2.   

Abstract

The Nrf2/heme oxygenase-1 (HO-1) axis affords significant protection against oxidative stress and cellular damage. We synthesized a series of cobalt-based hybrid molecules (HYCOs) that combine an Nrf2 inducer with a releaser of carbon monoxide (CO), an anti-inflammatory product of HO-1. Two HYCOs markedly increased Nrf2/HO-1 expression, liberated CO and exerted anti-inflammatory activity in vitro. HYCOs also up-regulated tissue HO-1 and delivered CO in blood after administration in vivo, supporting their potential use against inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26730678     DOI: 10.1021/acs.jmedchem.5b01509

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Soy-derived phytoalexins: mechanism of in vivo biological effectiveness in spite of their low bioavailability.

Authors:  Jisun Oh; Chan Ho Jang; Jong-Sang Kim
Journal:  Food Sci Biotechnol       Date:  2018-10-25       Impact factor: 2.391

2.  Carbon monoxide-induced metabolic switch in adipocytes improves insulin resistance in obese mice.

Authors:  Laura Braud; Maria Pini; Lucie Muchova; Sylvie Manin; Hiroaki Kitagishi; Daigo Sawaki; Gabor Czibik; Julien Ternacle; Geneviève Derumeaux; Roberta Foresti; Roberto Motterlini
Journal:  JCI Insight       Date:  2018-11-15

Review 3.  "CO in a pill": Towards oral delivery of carbon monoxide for therapeutic applications.

Authors:  Xiaoxiao Yang; Wen Lu; Minjia Wang; Chalet Tan; Binghe Wang
Journal:  J Control Release       Date:  2021-09-02       Impact factor: 11.467

Review 4.  Heme Oxygenase-1 and Carbon Monoxide in the Heart: The Balancing Act Between Danger Signaling and Pro-Survival.

Authors:  Leo E Otterbein; Roberta Foresti; Roberto Motterlini
Journal:  Circ Res       Date:  2016-06-10       Impact factor: 17.367

5.  Heme Oxygenase-1, a Key Enzyme for the Cytoprotective Actions of Halophenols by Upregulating Nrf2 Expression via Activating Erk1/2 and PI3K/Akt in EA.hy926 Cells.

Authors:  Xiu E Feng; Tai Gang Liang; Jie Gao; De Peng Kong; Rui Ge; Qing Shan Li
Journal:  Oxid Med Cell Longev       Date:  2017-06-14       Impact factor: 6.543

6.  Organometallic Nucleosides: Synthesis and Biological Evaluation of Substituted Dicobalt Hexacarbonyl 2'-Deoxy-5-oxopropynyluridines.

Authors:  Renata Kaczmarek; Dariusz Korczyński; Karolina Królewska-Golińska; Kraig A Wheeler; Ferman A Chavez; Agnieszka Mikus; Roman Dembinski
Journal:  ChemistryOpen       Date:  2018-01-18       Impact factor: 2.911

7.  Exploring the Protective Effects and Mechanism of Crocetin From Saffron Against NAFLD by Network Pharmacology and Experimental Validation.

Authors:  Zijin Xu; Susu Lin; Junjie Gong; Peishi Feng; Yifeng Cao; Qiaoqiao Li; Yuli Jiang; Ya You; Yingpeng Tong; Ping Wang
Journal:  Front Med (Lausanne)       Date:  2021-06-09

8.  Agmatine Reduces Lipopolysaccharide-Mediated Oxidant Response via Activating PI3K/Akt Pathway and Up-Regulating Nrf2 and HO-1 Expression in Macrophages.

Authors:  Jianshen Chai; Li Luo; Fengyan Hou; Xia Fan; Jing Yu; Wei Ma; Wangqi Tang; Xue Yang; Junyu Zhu; Wenyuan Kang; Jun Yan; Huaping Liang
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

9.  Vitexin attenuates lipopolysaccharide-induced acute lung injury by controlling the Nrf2 pathway.

Authors:  Ying Lu; Ting Yu; Jingyao Liu; Lina Gu
Journal:  PLoS One       Date:  2018-04-25       Impact factor: 3.240

10.  Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway.

Authors:  Navid Koleini; Barbara E Nickel; Jie Wang; Zeinab Roveimiab; Robert R Fandrich; Lorrie A Kirshenbaum; Peter A Cattini; Elissavet Kardami
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.